oral brain-penetrant NLRP3 inhibitor prodrug Ph. Ib/IIa for cardiovascular risk and neuroinflammation from SAR and prodrug development of known NLRP3 inhibitor CP-456,773 J. Med. Chem., October 2023 Nodthera, Essex, UK